Union Korea Pharm Completes Election of New Board at Extraordinary General Meeting to Implement Rehabilitation Plan

Union Korea Pharm held an extraordinary general meeting on July 21, 2026, and approved all agenda items to elect a new board of directors as part of the court-approved rehabilitation plan.
Two inside directors including new CEO Kwang-Hyun Sung and two outside directors were appointed with 75.3% approval from total outstanding voting shares.
All proposed removal of previous directors were withdrawn due to their resignations.
[AI Summary]Union Korea Pharm has taken the first step toward normalization by formally appointing a new management team under the rehabilitation process. While the new directors bring strong credentials, the company remains under court receivership, warranting caution on short-term share price volatility.